COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Biopsy
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
Disease Models, Animal
Host-Pathogen Interactions
/ immunology
Humans
Immunoglobulin G
Immunohistochemistry
Mice
Outcome Assessment, Health Care
RNA, Messenger
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
T-Lymphocyte Subsets
/ immunology
Vaccines, Synthetic
/ administration & dosage
mRNA Vaccines
COVID-19
SARS-CoV-2
T cells
mRNA vaccine
mRNA-1273
neutralizing antibodies
protective immunity
type 2 responses
vaccine-associated enhanced respiratory disease
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
10 08 2021
10 08 2021
Historique:
received:
18
02
2021
revised:
30
04
2021
accepted:
25
06
2021
pubmed:
17
7
2021
medline:
24
8
2021
entrez:
16
7
2021
Statut:
ppublish
Résumé
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndrome (SARS) and MERS coronavirus vaccines. We used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 10, lethal challenge virus (MA10) mouse model of acute lung injury to evaluate the immune response and potential for immunopathology in animals vaccinated with research-grade mRNA-1273. Whole-inactivated virus or heat-denatured spike protein subunit vaccines with alum designed to elicit low-potency antibodies and Th2-skewed CD4
Identifiants
pubmed: 34270939
pii: S1074-7613(21)00262-4
doi: 10.1016/j.immuni.2021.06.018
pmc: PMC8249710
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
RNA, Messenger
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1869-1882.e6Subventions
Organisme : NIAID NIH HHS
ID : U01 AI149644
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260543
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests O.M.A., K.S.C., and B.S.G. are inventors on pending patent applications related to coronavirus vaccines. S.R.L. and R.S.B. have pending patents on recombinant viruses used in this study. A.T.D., D.K.E., and A.C. are current employees and shareholders of Moderna, Inc. Other authors declare no competing interests.